pelacarsen Cardiovascular, Renal and Metabolic Phase 3 2026 ASO targeting Lp(a) Secondary prevention of cardiovascular events in patients with elevated levels of lipoprotein(a) (CVRR-Lp(a)) Lead Indication PrintPDF